| Autor: |
Ingo K. Mellinghoff, Timothy F. Cloughesy, Minesh P. Mehta, Paul S. Mischel, John G. Kuhn, William H. Yong, Lisa M. DeAngelis, Andrew B. Lassman, Nian Wu, Steve Horvath, Howard A. Fine, Michael D. Prados, Susan M. Chang, Kathleen R. Lamborn, Patrick Y. Wen, Jan Drappatz, David A. Reardon, Mark R. Gilbert, W. K. Alfred Yung, Frank Lieberman, Linda M. Liau, Adriana Heguy, Cameron W. Brennan, Alicia Pedraza, Julie Dang, Daisuke Kuga, Akio Iwanami, Shaojun Zhu, Hui Tao, Nicolas Yannuzzi, Milan G. Chheda, Barbara Oldrini, Sara Kubek, Phioanh Leia Nghiemphu, Christian Grommes, Carl Campos, Daniel Rohle, H. Ian Robins, Igor Vivanco |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.22529031.v1 |
| Popis: |
mp3 file (11 MB). In the May edition of the Cancer Discovery podcast, Science Writer Elizabeth McKenna talks with Ingo K. Mellinghoff about his paper, which suggests that the disappointing clinical activity of first-generation EGFR inhibitors in glioblastoma versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these two cancer types. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
